Trexquant Investment’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Trexquant Investment’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-54,239	Closed	-$271K	–	1627
2021 Q1	$271K	Buy	54,239 +39,665	+272%	+$321K	0.02%	808
2020 Q4	$184K	Buy	+14,574	New	+$166K	0.02%	905
2020 Q2	–	Sell	-17,631	Closed	-$156K	–	1571
2020 Q1	$156K	Buy	+17,631	New	+$174K	0.01%	1007
2019 Q3	–	Sell	-11,534	Closed	-$138K	–	1183
2019 Q2	$138K	Sell	11,534 -4,334	-27%	-$46.6K	0.01%	724
2019 Q1	$192K	Buy	+15,868	New	+$234K	0.01%	876
2017 Q1	–	Sell	-22,288	Closed	-$229K	–	1383
2016 Q4	$229K	Buy	+22,288	New	+$204K	0.04%	763
2016 Q2	–	Sell	-49,568	Closed	-$677K	–	1176
2016 Q1	$677K	Buy	49,568 +25,488	+106%	+$367K	0.08%	425
2015 Q4	$457K	Buy	+24,080	New	+$523K	0.04%	718

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Trexquant Investment's CNCE Position: Q2 2021 in Review

Trexquant Investment sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 54,239 shares — an estimated $271K sold.

Trexquant Investment first reported a position in CNCE in Q4 2015 and held it in 8 quarters. The position peaked at $677K in Q1 2016. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

Trexquant Investment reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Trexquant Investment sold 54,239 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $271K.
Trexquant Investment first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 8 quarters.
Trexquant Investment's Concert Pharmaceuticals, Inc. position peaked at $677K in Q1 2016.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on Trexquant Investment's 13F filing for Q2 2021, filed 12 Aug 2021.